In 1985, Bernard Bihari, MD, described the effects of low dose Naltrexone (1.5-4.5 mg Naltrexone) on the body's immune system. He discovered that people with HIV had less than twenty percent of the normal level of endorphins. He began looking for ways to raise endorphin without blocking its receptors and found that 1.75-4.5 mg Naltrexone (Low Dose Naltrexone, LDN) at bed time raises the endorphin level up to 100 to 300 percent during the night. Dr. Bihari has reported beneficial effects of LDN on a variety of diseases such as cancers (e.g. Multiple Myeloma, Lymphoma, Hodgkin's disease, breast cancer, GI cancers, non small cell cancer of lung, malignant melanoma, neuroblastoma, ovarian cancer, prostate cancer, renal cell carcinoma, and uterine cancer), amyotrophic lateral sclerosis, Alzheimer's disease, Behçet's disease, celiac disease, chronic fatigue syndrome, Crohn's disease, emphysema, fibromyalgia, HIV/AIDS, Irritable bowel syndrome, Parkinson's disease, pemphigoid, psoriasis, multiple sclerosis, rheumatoid arthritis, systemic Lupus erythematosus, ulcerative colitis and Wegner's granulomatosis . Despite these anecdotal claims there are no published studies demonstrating efficacy of LDN in any disease state.